Related Experiment Video
Updated: Mar 31, 2026
Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas
Published on: February 28, 2019
Clinical and prognostic analysis in 32 pediatric nasopharyngeal carcinoma
1Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou 310022, Zhejiang Province, China.
Insights
Prognostic factors for pediatric nasopharyngeal carcinoma (NPC) include N stage, chemotherapy, and radiotherapy dose. Patients with N2-3 disease benefit from combined chemotherapy and radiotherapy for improved survival outcomes.
Area of Science:
- Pediatric Oncology
- Radiation Oncology
- Medical Oncology
Background:
- Nasopharyngeal carcinoma (NPC) is rare in children but requires specific treatment strategies.
- Understanding prognostic factors is crucial for optimizing treatment and improving outcomes in pediatric NPC.
Purpose of the Study:
- To analyze clinical outcomes and prognostic factors in pediatric NPC.
- To establish a basis for rational treatment and enhance cure rates.
Main Methods:
- Retrospective analysis of 32 pediatric NPC patients (aged 11-18).
- All patients received intensity-modulated radiation therapy (IMRT) with specific dose prescriptions.
- 29 patients underwent chemotherapy; survival rates were analyzed using Kaplan-Meier and Cox models.
Main Results:
- Median survival time was 44.5 months; median follow-up was 62.5 months.
- Overall 1-, 3-, and 5-year survival rates were 97.2%, 90.5%, and 74.2%.
- Univariate analysis identified N stage, chemotherapy, and radiotherapy dose as significant prognostic factors; multivariate analysis confirmed N stage as the sole independent factor.
Conclusions:
- N stage, chemotherapy, and radiotherapy dose are key prognostic factors in pediatric NPC.
- Combined chemotherapy and radiotherapy are recommended for patients with N2-3 stage disease.
Objectives:
To analyze the clinical outcome and prognostic factors of pediatric nasopharyngeal carcinomas, provide the basis for the rational treatment, and improve the cure rate.
Materials And Methods:
Thirty-two pediatric nasopharyngeal carcinoma patients with pathologically confirmed diagnosis and aged from 11 to 18 years old were retrospectively analyzed. All patients received intensity-modulated radiation therapy, dose of GTVnx 6400-7425 cGy, PGTVnx 6400-7050 cGy, PTV 15,400-6000 cGy, PTV 25,000-5490 cGy, and GTVnd 6000-6996 cGy were given. Among these patients, 29 received various chemotherapies. The Kaplan-Meier test and log-rank test of SPSS 17.0 statistic software package were used to calculate survival rate, compare and analyze the survival rates of each group. Cox model was used to analyzing the prognosis factors.
Results:
In this study, the median survival time was 44.5 months, and the median follow-up time is 62.5 months. The 1-, 3-, and 5-year overall survival rates were 100.0%, 93.2%, 85.7%, respectively, in stage III, and 94.8%, 88.3%, and 64.7% in stage IV. All patients 1-, 3-, and 5-year overall survival rates were 97.2%, 90.5%, and 74.2%. Univariate analysis resulted that N stage (P = 0.043), chemotherapy (P = 0.003) and the radiotherapy dose (P = 0.028) were significant factors for survival. On multivariate analysis, only the N stage influence survival.
Conclusions:
In pediatric nasopharyngeal carcinoma, the more important prognostic factors are N stage, chemotherapy, radiotherapy dose. Patients with N2-3 should be treated with combined chemotherapy and radiotherapy.
